Interview with Alex Mayweg, partner at Versant Ventures and president of Ridgeline, a Versant Ventures Discovery Engine – Located in the Technologiepark Basel
“We make no compromises in creating the highest potential Company”
Versant Ventures has a strong history in building successful companies such as Therachon, Black Diamond or CRISPR Therapeutics. We talked to Alex Mayweg, partner at Versant Ventures in Basel, about the beauty of Versant Ventures discovery engine Ridgeline Therapeutics, translating science into successful drug development programs and the future of drug discovery.
Aurealis Pharma Announces 7.8M CHF Financing
Cellestia Biotech AG successfully closes Series A financing ...
Strekin AG today Announces the Publication of Key in vivo Da...
Bioversys at the forefront of antibiotic research
Swiss Technology Award 2018